posted on June 10, 2010 at 9:50 am
BRCA NEWSWORTHY
ASCO Update: Emerging agents to change the landscape of ovarian cancer treatment
June 8, 2010 Analysis by: Jason Tse
ASCO or the American Society of Clinical Oncology has recently come out & said that they have had “encouraging” results with parp inhibitor drugs when combined with chemotherapy in the fight against breast & ovarian cancer. These drugs are Avastin, olaparib, AMG386, farletuzumab & voreloxin. Avastin is the frontrunner in these drugs & hopefully will be approved in 2011 to fight Ovarian Cancer.
Follow this link for this very interesting, promising news!
